Den europeiske union -
norsk -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Den europeiske union -
norsk -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
fampridine accord
accord healthcare s.l.u. - fampridine - multippel sklerose - andre nervesystemet narkotika - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).
Norge -
norsk -
Statens legemiddelverk
levetiracetam aristo 100 mg/ ml
aristo pharma gmbh - levetiracetam - mikstur, oppløsning med druesmak - 100 mg/ ml
Norge -
norsk -
Statens legemiddelverk
omnipaque 350 mg i/ ml
ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 350 mg i/ ml
Norge -
norsk -
Statens legemiddelverk
omnipaque 140 mg i/ ml
ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 140 mg i/ ml
Norge -
norsk -
Statens legemiddelverk
omnipaque 180 mg i/ ml
ge healthcare as - joheksol - injeksjonsvæske, oppløsning - 180 mg i/ ml